Cytidylyl cyclase activity of bacterial exotoxins by Göttle, Martin et al.
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
BMC Pharmacology
Open Access Poster presentation
Cytidylyl cyclase activity of bacterial exotoxins
Martin Göttle1, Frieder Kees1 and Roland Seifert*2
Address: 1Department of Pharmacology and Toxicology, University of Regensburg, Germany and 2Department of Pharmacology, Hannover 
Medical School, Germany
Email: Roland Seifert* - seifert.roland@mh-hannover.de
* Corresponding author    
3',5'-Cyclic adenosine monophosphate (cAMP) and 3',5'-
cyclic guanosine monophosphate (cGMP) are key second
messengers for a wide variety of mammalian cellular proc-
esses. The natural occurrence of a third cyclic nucleotide,
3',5'-cyclic cytidine monophosphate (cCMP) had been
discussed very controversially 30–35 years ago [1-3], but
later, cCMP was identified unambiguously in various
mammalian tissues [4] indicating cCMP to be a novel sec-
ond messenger with potential importance in regulation of
cell growth, proliferation, tissue development and modu-
lation of immune responses [5]. However, the precise
identity of the cCMP-forming enzyme in mammalian cells
is still unclear. Here, for the first time, we provide evi-
dence for cytidylyl cyclase (CC) activity of purified bacte-
rial exotoxins.
Bacillus anthracis and Bordetella pertussis, the causative bac-
teria of anthrax disease and whooping cough, respectively,
secrete the adenylyl cyclase(AC) toxins edema factor (EF)
and CyaA, weakening immune responses through massive
cAMP production and, thereby, promoting the pathogen-
esis of the infections [6]. We found that both toxins also
possess cytidylyl cyclase activity, resulting in the conver-
sion of CTP to cCMP.
In our CC activity assay, the radioactively labeled sub-
strate [α-32P]CTP is converted to [32P]cCMP which is
quantified by liquid scintillation. Upon incubation of the
toxins with [α-32P]CTP, [32P]cCMP is produced in a linear
manner over time. As [32P]cCMP production depends on
the endogenous toxin activator protein calmodulin, as
physiological pH promotes the reaction and as potent AC
inhibitors show high potency on EF and CyaA, catalysis
results from specific CC activity. Michaelis-Menten kinet-
ics of EF CC activity yielded Km = 13 ± 3 μM and Vmax = 8
± 1 s-1.
When CTP consumption and cCMP formation were mon-
itored by HPLC, 100 μM CTP were converted to cCMP by
20 nM EF within 1 h. In the presence of heat-inactivated
enzyme, no cCMP was formed. The identity of cCMP was
confirmed by co-eluting standard cCMP in HPLC experi-
ments and by mass spectrometry methods. Based on these
findings and the fact that cCMP inhibits host immune
responses [7,8], we propose that the bacterial exotoxins
edema factor (EF) and CyaA generate cCMP, resulting in
increased infection severity. The molecular targets of
cCMP remain to be determined.
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